Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

Abstract

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on intraperitoneal therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop.

• Authors: D S Alberts, M Markman, F Muggia, R F Ozols, E Eldermire, M A Bookman, T Chen, J Curtin, L M Hess, L Liebes, R C Young, E Trimble
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 103 Issue 3 Pg. 783-92 (Dec 2006) ISSN: 0090-8258 [Print] United States
• PMID: 17070570 (Publication Type: Consensus Development Conference, Journal Article)

Chemical References

• Paclitaxel
• Cisplatin

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Congresses as Topic
• Disease-Free Survival
• Female
• Humans
• Injections, Intraperitoneal
• Ovarian Neoplasms (drug therapy, mortality, nursing)
• Paclitaxel (administration & dosage)
• Randomized Controlled Trials as Topic
• Survival Analysis
• United States